Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Non-Muscle Invasive Papillary Urothelial Carcinoma Metastatic to the Mandible.

Frydenlund N, Zakharia Y, Garje R, Dahmoush L, O'Donnell MA.

J Investig Med High Impact Case Rep. 2018 Oct 16;6:2324709618806332. doi: 10.1177/2324709618806332. eCollection 2018 Jan-Dec.

2.

Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer.

Fox E, Oliver T, Rowe M, Thomas S, Zakharia Y, Gilman PB, Muller AJ, Prendergast GC.

Front Oncol. 2018 Sep 11;8:370. doi: 10.3389/fonc.2018.00370. eCollection 2018. Review.

3.

Autoimmune retinopathy and optic neuropathy associated with enolase-positive renal oncocytoma.

Cheng JL, Beebe JD, Nepple KG, Zakharia Y, Mullins RF, Flamme-Wiese MJ, Thurtell MJ, Han IC.

Am J Ophthalmol Case Rep. 2018 Sep 10;12:55-60. doi: 10.1016/j.ajoc.2018.09.005. eCollection 2018 Dec.

4.

Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.

Muller AJ, Manfredi MG, Zakharia Y, Prendergast GC.

Semin Immunopathol. 2018 Sep 10. doi: 10.1007/s00281-018-0702-0. [Epub ahead of print] Review.

PMID:
30203227
5.

Toxicities with targeted therapies after immunotherapy in metastatic melanoma.

Grogan N, Swami U, Bossler AD, Zakharia Y, Milhem M.

Melanoma Res. 2018 Dec;28(6):600-604. doi: 10.1097/CMR.0000000000000493.

PMID:
30086073
6.

Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces Together.

Swami U, Zakharia Y, Zhang J.

J Immunother. 2018 Oct;41(8):359-360. doi: 10.1097/CJI.0000000000000232.

PMID:
29781826
7.

Selenium targets resistance biomarkers enhancing efficacy while reducing toxicity of anti-cancer drugs: preclinical and clinical development.

Zakharia Y, Bhattacharya A, Rustum YM.

Oncotarget. 2018 Jan 23;9(12):10765-10783. doi: 10.18632/oncotarget.24297. eCollection 2018 Feb 13. Review.

8.

Targeting epigenetics for treatment of BRAF mutated metastatic melanoma with decitabine in combination with vemurafenib: A phase lb study.

Zakharia Y, Monga V, Swami U, Bossler AD, Freesmeier M, Frees M, Khan M, Frydenlund N, Srikantha R, Vanneste M, Henry M, Milhem M.

Oncotarget. 2017 Sep 26;8(51):89182-89193. doi: 10.18632/oncotarget.21269. eCollection 2017 Oct 24.

9.

Acute Flare of Bullous Pemphigus With Pembrolizumab Used for Treatment of Metastatic Urothelial Cancer.

Garje R, Chau JJ, Chung J, Wanat K, Zakharia Y.

J Immunother. 2018 Jan;41(1):42-44. doi: 10.1097/CJI.0000000000000191.

PMID:
29111983
10.

Quality-of-life outcomes in patients with advanced melanoma: A review of the literature.

Malkhasyan KA, Zakharia Y, Milhem M.

Pigment Cell Melanoma Res. 2017 Jan;30(6):511-520. doi: 10.1111/pcmr.12647. Epub 2017 Oct 13. Review.

PMID:
28950054
11.

Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy.

Venur VA, Joshi M, Nepple KG, Zakharia Y.

Drug Des Devel Ther. 2017 Apr 11;11:1175-1182. doi: 10.2147/DDDT.S110209. eCollection 2017. Review.

12.

Ipilimumab: from preclinical development to future clinical perspectives in melanoma.

Letendre P, Monga V, Milhem M, Zakharia Y.

Future Oncol. 2017 Mar;13(7):625-636. doi: 10.2217/fon-2016-0385. Epub 2016 Nov 24. Review.

13.

Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease: A Report of 2 Patient Cases.

Phadke SD, Ghabour R, Swick BL, Swenson A, Milhem M, Zakharia Y.

J Investig Med High Impact Case Rep. 2016 Oct 25;4(4):2324709616674316. eCollection 2016 Oct-Dec.

14.

Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma.

Zakharia Y, Zakharia K, Rixe O.

Expert Opin Drug Discov. 2015;10(8):925-35. doi: 10.1517/17460441.2015.1045411. Epub 2015 Jun 3. Review.

PMID:
26039031
15.

Ovarian cancer from an immune perspective.

Zakharia Y, Rahma O, Khleif SN.

Radiat Res. 2014 Aug;182(2):239-51. doi: 10.1667/RR13741.1. Epub 2014 Jul 18. Review.

PMID:
25036981
16.

Tumor Lysis Syndrome in a Retroperitoneal Sarcoma.

Zakharia Y, Mansour J, Vasireddi S, Zakharia K, Fatakhov E, Koch C, Hrinczenko B.

J Investig Med High Impact Case Rep. 2014 Jul 4;2(3):2324709614542340. doi: 10.1177/2324709614542340. eCollection 2014 Jul-Sep.

17.

HER2 testing: how to reach a high concordance rate between immunohistochemistry and fluorescence in situ hybridization.

Khoury T, Kulkarni S, Morrison C, Bshara W, Zakharia Y, Edge S.

Appl Immunohistochem Mol Morphol. 2011 Oct;19(5):424-30. doi: 10.1097/PAI.0b013e31820b62be.

PMID:
21386703
18.

The effect of various vitamin D supplementation regimens in breast cancer patients.

Peppone LJ, Huston AJ, Reid ME, Rosier RN, Zakharia Y, Trump DL, Mustian KM, Janelsins MC, Purnell JQ, Morrow GR.

Breast Cancer Res Treat. 2011 May;127(1):171-7. doi: 10.1007/s10549-011-1415-4. Epub 2011 Mar 8.

19.

Breast hormonal receptors test should be repeated on excisional biopsy after negative core needle biopsy.

Khoury T, Zakharia Y, Tan W, Kulkarni S, Liu W, Zhang S, Wilding GE, Edge S.

Breast J. 2011 Mar-Apr;17(2):180-6. doi: 10.1111/j.1524-4741.2010.01051.x. Epub 2011 Feb 10.

PMID:
21306471
20.

Lung cancer in the very elderly: incidence, presentation, and diagnostic decision-making. A retrospective analysis at a teaching community hospital.

Ayyappan S, Gonzalez C, Yarlagadda R, Zakharia Y, Woodlock TJ.

J Community Hosp Intern Med Perspect. 2011 Oct 17;1(3). doi: 10.3402/jchimp.v1i3.7313. Print 2011.

Supplemental Content

Loading ...
Support Center